11:43 AM EST - Valeant Pharmaceuticals International, Inc. : Announced third-quarter financial results for 2015. Valeant Pharmaceuticals International, Inc. Total Revenues were $2.8 billion; an increase of 36% over the prior year despite negative foreign exchange impact of $172 million. GAAP EPS was $0.14; Cash EPS was $2.74, an increase of 30% over prior year despite the negative foreign exchange impact of $0.13 versus the prior year. Valeant Pharmaceuticals International, Inc.
shares T.VRX are trading down $8.48 at $218.92.
